Biopharma: Clinical Trial Pipeline Tracker

Research evidence excerpt

Biopharma: Clinical Trial Pipeline Tracker

Update

July 16, 2026 08:01 PM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

Clinical Trial Pipeline Tracker Terence.Flynn@morganstanley.comSean Laaman, Ph.D. +1 212 761-2230

Sean.Laaman@morganstanley.com +1 212 761-4947

We highlight key changes to the clinical trials of companies Michael E Ulz

under coverage occurring from 7/8-7/15. See inside for a full list EquityMike.Ulz@morganstanley.comAnalyst +1 212 761-4650

of changes. Judah C. Frommer, CFA

Judah.Frommer@morganstanley.com +1 212 761-1270

Maxwell SkorMNew Trials ( Exhibit 1 ) Equity Analyst

Maxwell.Skor@morganstanley.com +1 212 761-4804

• Abbvie: The company has initiated a Ph2 Trial (NCT07697456) of Advanced Chris Yu, J.D., Ph.D.

Therapies for the Treatment of Adult Participants With Moderately to Equity Analyst

Chris.L.Yu@morganstanley.com +1 212 761-2535

Severely Active Crohn's Disease or Ulcerative Colitis Alexander Yevdokimov, Ph.D.

• Regeneron: The company has initiated a Ph3 trial (NCT07697599) for Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and

Connor M Massari

REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Equity Analyst

Central Catheter (PICC) Connor.Massari@morganstanley.com +1 212 761-2417

Michael H Riad, Ph.D.

Research Associate

Terminated ( Exhibit 2 ) Michael.Riad@morganstanley.com +1 212 761-1309

Katherine Sun

• BeOne Medicines: The Ph1 trial (NCT05828589) of BGB-21447, a Bcl-2 Research Associate

Katherine.Sun@morganstanley.com +1 212 761-5968

Inhibitor, in Mature B-Cell Malignancies was terminated Hailey Horowitz

Hailey.Horowitz@morganstanley.com +1 212 761-5264

Recruiting ( Exhibit 3 )